Trial reportChinese medical journal2016
Efficacy and Safety of Esmolol in Treatment of Patients with Septic Shock.
Trial report in Chinese medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01920776 (Focused Ultrasound in Septic Shock Patients), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Focused Ultrasound in Septic Shock Patients
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials.Critical care (London, England) · 2024Pooled it
- The role of esmolol in sepsis: a meta-analysis based on randomized controlled trials.BMC anesthesiology · 2024Pooled it
- Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review.Clinical drug investigation · 2019Pooled it
- The pros and cons of beta-blockers in sepsis: Where do we stand in 2024?Journal of intensive medicine · 2025Article
- Metoprolol use is associated with improved outcomes in patients with sepsis-induced cardiomyopathy: an analysis of the MIMIC-IV database.BMC cardiovascular disorders · 2024Observational
- The influence of metoprolol in patients with sepsis-induced cardiomyopathy: A retrospective study.Saudi medical journal · 2023Article
- Role of adrenergic receptors in shock.Frontiers in physiology · 2023Review
- Role of aspirin, beta-blocker, statins, and heparin therapy in septic patients under mechanical ventilation: a narrative review.Frontiers in medicine · 2023Review
- Stepwise lactate kinetics in critically ill patients: prognostic, influencing factors, and clinical phenotype.BMC anesthesiology · 2021Article
- Beta-Adrenergic Blockade in Critical Illness.Frontiers in pharmacology · 2021Review
- Challenges in the management of septic shock: a narrative review.Intensive care medicine · 2019Review
- Article
- The influence of esmolol on right ventricular function in early experimental endotoxic shock.Physiological reports · 2018Article
- Esmolol infusion in patients with septic shock and tachycardia: a prospective, single-arm, feasibility study.Pilot and feasibility studies · 2018Article
- Outpatient beta-blockers and survival from sepsis: Results from a national cohort of Medicare beneficiaries.American journal of surgery · 2017Article
- Monitoring Changes in Hepatic Venous Velocities Flow after a Fluid Challenge Can Identify Shock Patients Who Lack Fluid Responsiveness.Chinese medical journal · 2017Article
- Left Ventricular Longitudinal Systolic Function in Septic Shock Patients with Normal Ejection Fraction: A Case-control Study.Chinese medical journal · 2017Article
- Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock.Critical care (London, England) · 2016Article
- Distributive shock in cardiac intensive care unit patients.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have suggested that β1-receptor blockers benefit septic shock patients. This study aimed to determine whether β1-receptor blockers benefit tissue perfusion in sepsis and to identify parameters to reduce the risk of this drug in sepsis.
methodsConsecutive septic shock patients were recruited from the Intensive Care Unit of Peking Union Medical College Hospital within 48 h of diagnosis. All patients were hemodynamically stable and satisfactorily sedated with a heart rate (HR) ≥100 beats/min. Esmolol therapy achieved the target HR of 10-15% lower than the baseline HR. Clinical and physiological data of patients were collected prospectively within 1 h prior to esmolol therapy and 2 h after achieving the targeted HR.
resultsSixty-three patients were recruited. After esmolol therapy, blood pressure was unaltered, whereas stroke volume (SV) was increased compared with before esmolol therapy (43.6 ± 22.7 vs. 49.9 ± 23.7 ml, t = -2.3, P = 0.047). Tissue perfusion, including lactate levels (1.4 ± 0.8 vs. 1.1 ± 0.6 mmol/L, t = 2.6, P = 0.015) and the central venous-to-arterial carbon dioxide difference (5.6 ± 3.3 vs. 4.3 ± 2.2 mmHg, t = 2.6 P = 0.016), was also significantly decreased after esmolol therapy. For patients with increased SV (n = 42), cardiac efficiency improved, and esmolol therapy had a lower risk for a decrease in cardiac output (CO). Therefore, pretreatment cardiac systolic and diastolic parameters with (n = 42)/without (n = 21) an increase in SV were compared. Mitral lateral annular plane systolic excursion (MAPSElat) in patients with increased SV was significantly higher than that in those without increased SV (1.3 ± 0.3 vs. 1.1 ± 0.2 cm, t = 2.4, P = 0.034).
conclusionsSV of septic shock patients is increased following esmolol therapy. Although CO is also decreased with HR, tissue perfusion is not worse. MAPSElat can be used to predict an increase in SV before esmolol use.
trial registrationClinicalTrials.gov, NCT01920776; https://clinicaltrials.gov/ct2/show/NCT01920776?term=NCT01920776&rank=1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.